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Autoimmune diseases aﬀect more than 50 million Americans, resulting in signiﬁcant healthcare costs. Most autoimmune diseases
occur sporadically; however, endemic pemphigus foliaceus (EPF) is an autoimmune skin disease localized to speciﬁc geographic
loci. EPF, and the related diseases pemphigus vulgaris (PV) and pemphigus foliaceus (PF), are characterized by skin lesions
and autoantibodies to molecules found on epidermal keratinocytes. A variant of EPF in patients from El Bagre, Colombia,
South America, has recently been reported to be distinct from previously described loci in Brazil and Tunisia epidemiologically
and immunologically. As in PF and EPF, El Bagre EPF patients exhibit autoantibodies towards desmoglein-1, a cell adhesion
molecule critical for maintaining epidermal integrity. An association of El Bagre EPF with sun exposure has been detected, and
ultraviolet irradiation also exacerbates symptoms in PV, PF and EPF. Our hypothesis is that: (1) the autoantibodies generate
pathology through an alteration in ceramide metabolism in targeted keratinocytes, resulting in apoptosis and/or cell death and
acantholysis, but only when the cell’s ability to metabolize ceramide is exceeded, and (2) apoptosis in response to this altered
ceramide metabolism is initiated and/or exacerbated by other agents that increase ceramide levels, such as cytokines, ultraviolet
irradiation, and senescence.
1.Introduction
More than 50 million Americans suﬀer from autoimmune
diseases. Because of the chronic nature of this group of
diseases, their treatment results in a tremendous cost to
healthcare as well as to serious reductions in the quality of
life of aﬀected individuals. Pemphigus refers to a class of
rare autoimmune skin diseases characterized by epithelial
blistering and acantholysis. Pemphigus vulgaris (PV) blisters
occur in mucosal tissues and the skin whereas the lesions
of pemphigus foliaceus (PF) exhibit a localization to the
suprabasal epidermis. The main pathogenic PV autoanti-
body recognizes desmoglein—(Dsg) 3, a desmosomal cad-
herin expressed in mucosaeand theepidermis. PFantibodies
are predominantly directed towards Dsg-1, another cell
adhesion molecule critical for the maintenance of epidermal
integrity. Most autoimmune diseases, including PV and PF,
occur sporadically and are widely scattered geographically.
However, endemic pemphigus foliaceus (EPF) represents
an autoimmune disorder that is limited to a well-deﬁned
geographic area (reviewed in [1, 2]), such as Brazil or, as
reviewed below, El Bagre, Columbia in South America [3].
This El Bagre EPF is also characterized by acantholytic skin
lesions and by autoantibodies to Dsg-1 [3–5]. However, the
mechanism by which the autoantibodies found in the sera of
p a t i e n t sw i t hE lB a g r eE P F ,a sw e l la sw i t hP V ,P F ,a n dE P F ,
result in the blistering skin lesions typical of pemphigus is
largely unknown.
2. ElBagreEndemicPemphigusFoliaceus(EPF)
A novel variant of EPF in patients from an area around
E1 Bagre, Colombia, South America was recently identiﬁed2 Dermatology Research and Practice
by Abreu-Velez and colleagues [3]. This focus of EPF is
distinct from previously described EPF foci in Brazil and
Tunisia both epidemiologically and immunologically. Thus,
patients with El Bagre EPF are typically men aged from
forty to sixty (with a few postmenopausal women), and
symptoms often resemble those of paraneoplastic pemphi-
gus, but without the accompanying malignancy [3]. The
autoantibody proﬁleof theseElBagreEPFpatients is distinct
from that of patients with the Brazilian form of EPF, also
known as fogo selvagem (see below). As with other EPF
foci as well as PF, the El Bagre disease is characterized
by skin lesions with hyperkeratosis, acanthosis, and acan-
tholysis. Immunoﬂuorescence studies indicate that the sera
of these patients possess autoantibodies that recognize an
antigen(s) on the keratinocyte cell surface producing typical
intercellular staining in the epidermis [4]. Approximately
two-thirds of the E1 Bagre EPF patients exhibit a form
localized to the skin; however, one-third develop a more
severe form characterized by systemic symptoms resembling
lupus. There also appears to be a genetic component to
the development of this disease, since certain ethnic groups
show a predisposition to acquire E1 Bagre EPF. On the
other hand, the involvement of environmental factors in the
development of El Bagre EPF is suggested by the restricted
geography (this EPF is limited to individuals living in
the area surrounding E1 Bagre) as well as the fact that
some patients have converted from the systemic to the
localized form of the disease after moving from the area
[3]. Additional evidence of an environmental parameter is
the ﬁnding of a strong association between the amount
of sun exposure and the development of the disease [3].
However, the precipitating factor(s) that triggers the disease
is unknown.
3. Immunologic Features of El Bagre EPF
Indirect immunoﬂuorescence (with El Bagre EPF sera)
on human skin sections revealed intercellular staining in
all patients, with some EPF sera also showing reactivity
with the basement membrane zone [4]. Approximately
10% of the control individuals from within, but not from
outside, the endemic area also demonstrated intercellular
immunoreactivity. Immunoprecipitation and immunoblot-
ting analyses indicated that the antigens recognized by the
EPF autoantibodies comigrated (by gel electrophoresis) with
Dsg-1, desmoplakin, envoplakin, and periplakin; and studies
using baculovirus-expressed desmosome-associated proteins
showed that these patients possess antibodies recognizing
Dsg-1, envoplakin, and periplakin [6]. Dsg-1 represents
an important antigen for the autoantibodies of patients
with fogo selvagem [7] as well; however, this study [6]
demonstrateda distinct immunoreactivity proﬁlein El Bagre
EPF versus fogo selvagem. These results again point to the
idea that El Bagre EPF represents a novel variant of the
disease. Nevertheless, the mechanism by which recognition
of Dsg-1, and perhaps other antigens, contributes to the
observed apoptosis [8, 9] and development of lesions in EPF
is not known [1].
4.Pemphigus and Apoptosis,Apoptolysis
andOncosis
Although it is appreciated that there is signiﬁcant apopto-
sis in pemphigus, there has been controversy concerning
whether or not apoptosis precedes and/or is required for
acantholysis (reviewed in [10]). Recent evidence suggests
that while other processes, such as oncosis [11], cell
shrinkage, and a process that has been termed apoptolysis
(reviewed in [12]), play a role in the development of
skin lesions, apoptotic cell death also clearly contributes
to acantholysis. Indeed, many investigators have reported
the ability of inhibitors of apoptosis-activated caspases to
inhibit acantholysis both in vitro and in vivo, in a passive
transfer mouse model of pemphigus ([11] and reviewed in
[12]). On the other hand, there seems to be some diﬀerences
in the mechanism of cell death induced by autoantibodies
from diﬀerent patients. Thus, Grando and colleagues [11]
found two subsets of PV autoantibodies: for one subset, cell
death seemed to be primarily initiated by caspase-dependent
processes (although calpain was also involved), and in the
other, calpain initiated cell death (although caspases also
contributed).
Data in the literature indicate that pemphigus sera are
able to trigger lipid metabolism in treated keratinocytes.
Based on an in-depth understanding of ceramide and
sphingolipid metabolism and the role of ceramide as a
mediator of apoptosis in multiple cell systems (reviewed
in [13, 14]) as well as data in the literature, we hypoth-
esize that pemphigus autoantibodies contribute to lesional
pathology by altering sphingomyelin metabolism to result in
elevated ceramide levels that trigger cell death via apoptosis
(Figure 1). Furthermore, we hypothesize that this process is
exacerbated in keratinocytes exposed to other agents that
aﬀectceramidemetabolism,suchascytokinesandultraviolet
(UV) irradiation (see below). This hypothesis represents a
novelinterpretationofthedataandcouldpotentiallyprovide
a mechanism by which autoantibodies lead to cell death and
apoptosis, oncosis and apoptolysis.
5. Ceramide As an Antiproliferative,
Proapoptotic Signal
Ceramides are well-known structural components of the
skin and help to form the water-permeability barrier of
the epidermis (reviewed in [15]). However, ceramide can
also function as a lipid second messenger. Approximately
two decades ago, investigators began reporting on the
ability of certain cytokines and other signals to activate
sphingomyelinase,anenzymethathydrolyzessphingomyelin
to form ceramide and phosphorylcholine (reviewed in [16]).
In addition, using synthetic ceramides to mimic the eﬀects
of sphingomyelinase-activating agents, researchers demon-
strated the ability of this lipid to function as a signaling
molecule, mediating a number of important eﬀects. Other
studies have shown that ceramide can be generated by a de
novo pathway initiated by serine palmitoyltransferase as well
(Figure 1), for instance, in response to chemotherapeuticDermatology Research and Practice 3
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Figure 1: Ceramide Metabolism. Ceramide is produced de novo via
serine palmitoyltransferase (SPT) and ceramide synthase (CerS), or
from sphingomyelin via sphingomyelinase (SMase), and induces
apoptosis. In turn, ceramide is metabolized via multiple mech-
anisms, including glucosylceramide synthase (GCS), ceramidase
(CDase) sphingosine kinase (SphK), and sphingomyelin synthase
(SMS), with this metabolism of ceramide allowing cell survival.
agents (reviewed in [13]). Most often, these increases in
ceramide are associated with growth arrest, diﬀerentiation,
senescence, and apoptosis, as has been shown in numerous
cell types (reviewed in [17]), including keratinocytes [18,
19]. In particular, ceramide produced in response to a
number of cell stresses has been shown to trigger apoptosis
(reviewed in [17]).
Interestingly,hyperproliferativecancercellsareoftenable
to evade the apoptosis triggered by agents that increase
ceramidebyutilizingmultiplemetabolicenzymestodecrease
ceramidebelowcriticallevels(reviewedin[20]).Asanexam-
ple,inmultidrug-resistantcellstheenzymeglucosylceramide
synthase (GCS), which glycosylates the ceramide induced
by chemotherapeutic agents to produce glucosylceramide
(Figure 1 a n dr e v i e w e di n[ 11]), is elevated. Overexpression
of GCS converts drug-sensitive cells to resistant ones,
whereas decreasing GCS levels with antisense constructs
changes resistant cells to a sensitive phenotype [21, 22].
This same enzyme also appears to protect keratinocytes
against ceramide-induced stress/apoptosis by converting
ceramide to glucosylceramide [23]. Similarly, virally trans-
formed cells (SV40-transformed human lung ﬁbroblasts)
exhibit increased sphingomyelin synthase activity [24]. Sph-
ingomyelin synthase transfers the choline headgroup from
phosphatidylcholine to ceramide to generate sphingomyelin
and diacylglycerol (Figure 2), thereby decreasing ceramide
levels. Ceramide can also be metabolized by ceramidase,
which hydrolyzes ceramide to sphingosine and is activated,
for instance, by growth factors (e.g., [25]). In general,
sphingosine is antiproliferative and/or proapoptotic, that is,
induces similar eﬀects to ceramide (reviewed in [26]). On
the other hand, sphingosine can be phosphorylated to yield
sphingosine 1-phosphate (S1P) by sphingosine kinase (of
which there are two identiﬁed isoforms, sphingosine kinase-
1 and -2). S1P can act as a ﬁrst messenger by binding to a
Phosphatidylcholine
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Diacylglycerol Ceramide
Sphingomyelin
Figure 2: Sphingomyelin synthase. The reaction catalyzed by
sphingomyelin synthase (SM synthase) results in a reduction in
ceramide and an increase in diacylglycerol and sphingomyelin
levels. The reported phosphatidylcholine-speciﬁc phospholipase C
inhibitor D609 also inhibits sphingomyelin synthase activity.
family of GTP-binding protein-coupled receptors, the S1P
receptors, but may also signal intracellularly (reviewed in
[27]).Inmostcases,S1Pmediatesproliferativecellresponses
and/or cell survival [27], with the combined activities of
ceramidase and sphingosine kinase possibly accounting for
the observation that in some cell types certain ceramide-
elevating agents increase proliferation. Thus, any agent that
increases ceramide levels might be expected to activate one
or more ceramide metabolic pathways as the cell strives
to reduce ceramide and protect itself from the apoptotic
eﬀects of this lipid signal. Indeed, 1,25-dihydroxyvitamin
D3-stimulated sphingomyelinase activation, which would be
expected to increase ceramide production, appears not to
induce apoptosis because of the concominant generation of
S1P [28], which in human keratinocytes S1P is reported
to be prodiﬀerentiative (e.g., [29]). In contrast, if ceramide
levels rise beyond a critical threshold, that is, above the levels
that can be metabolized by the various ceramide metabolic
pathways apoptosis might be anticipated to result.
6. Pemphigus and Ceramide
Seishima et al. [30] investigated the eﬀect of PV autoanti-
bodies on signaling processes in DJM-1 cells, a squamous
cell carcinoma cell line. These authors found that addition
of immunoglobulins from pemphigus patients increased
the levels of diacylglycerol derived from phosphatidyl-
choline. This increase was not the result of activation of
phosphatidylcholine-hydrolyzing phospholipase D, resulted
inthereleaseofphosphorylcholineandcouldbeinhibitedby
D609. Furthermore, preadsorption of the immunoglobulins
with Dsg-1 and -3 prevented the signaling eﬀect [30].
Stanley and colleagues have suggested that autoantibodies
to either Dsg-1 or -3 can produce blisters in pemphigus
diseases, with the location of the lesions dependent on the
distribution of these two molecules in various epithelia [31].
Thus, antibodies directed at either of these desmosomal
components should induce similar eﬀects, and anti-Dsg
antibodies present in PV, PF, or EPF, including El Bagre EPF,
would be expected to trigger the same signaling events as
those elicited by the autoantibodies in PV sera. Seishima et
al. suggested that the pemphigus autoantibodies activate a
phosphatidylcholine-speciﬁcphospholipaseC[30];however,
no such enzyme has as yet been puriﬁed and/or cloned in4 Dermatology Research and Practice
mammals. In addition, it has been shown that D609 inhibits
sphingomyelin synthase [24, 32] in addition to (or instead
of) the reported phosphatidylcholine-speciﬁc phospholipase
C. As mentioned previously, sphingomyelin synthase trans-
fers the choline headgroup from phosphatidylcholine to
ceramide to form diacylglycerol and sphingomyelin (see
above and Figure 2). Because phosphatidylcholine is “con-
sumed” and diacylglycerol is generated by this enzyme, it is
diﬃcult to distinguish between the activity of sphingomyelin
synthase and that of a hypothetical phosphatidylcholine-
speciﬁc phospholipase C without monitoring sphingolipid
metabolism.Thus,theideathatthepemphigusautoantibod-
ies activate a sphingomyelinase to generate ceramide (and
releasephosphorylcholine),andthisceramideismetabolized
by sphingomyelin synthase (to decrease phosphatidylcholine
and increase diacylglycerol) is consistent with the observed
ﬁndings.
The possible involvement of ceramide in the pathology
of the skin lesions is also consistent with the observed asso-
ciation of El Bagre EPF disease with certain environmental
factors such as sun exposure [3]. Sun exposure has also
been reported as an exacerbating factor in PV, PF, and fogo
selvagem(e.g.,[33,34])(seebelow).UVirradiationisknown
to raise ceramide levels in keratinocytes [19, 35], as do many
cell stresses in other cell types (reviewed in [36]), suggesting
that the autoantibodies in and of themselves may not be
pathogenic without some additional perturbation of the
cells. Indeed, relatives of the El Bagre EPF patients have been
observed to possess immunoreactivity to EPF antigens, as
measured by immunoprecipitation, immunoblotting [5, 6],
and an enzyme-linked immunosorbent assay (ELISA) [37],
yet these individuals show no evidence of disease [3, 37].
A similar phenomenon has been observed in fogo selvagem
(BrazilianEPF)[38],and,inaddition,fogoselvagemautoan-
tibodies are also known to bind to oral mucosa but do not
induce lesion formation [39]. On the other hand, cytokines,
such as tumor necrosis factor-alpha (TNF-α), interleukin-
1 (IL-1), and interferon gamma (IFNγ), are all known to
elevate ceramide levels ([40] and reviewed in [41, 42]) and
are present in the lesions of autoimmune skin diseases [43–
45]. Thus, environmental factors that elevate the quantities
of these agents may contribute to the cell perturbations that
result in pathology of the autoantibodies. Indeed, Puviani
et al. [8] have demonstrated that pemphigus sera contain
high levels of Fas ligand (FasL). FasL is also a well-known
activator of ceramide production through sphingomyelinase
activation(reviewedin[41])andmaystressthekeratinocytes
suﬃciently that they may be unable to metabolize the
ceramide below apoptotic levels. If ceramide cannot be
reduced below certain levels, the keratinocyte would be
triggered to undergo apoptosis, as has been seen in anti-
FasL-treated cultured keratinocytes [46] and in acantholytic
lesions in pemphigus (reviewed in [10]). Finally, Wang
et al. [47] have demonstrated that replicative senescence
enhances the apoptotic eﬀect of pemphigus autoantibodies.
Ceramide levels are known to be elevated in senescence
[48, 49], providing another link between ceramide and
apoptotic cell death in pemphigus. Thus, we hypothesize
that the autoantibodies, and perhaps FasL [8, 50], and/or
othercytokines,presentinpemphigusseraincreaseceramide
levels and in conjunction with other cell stresses, such as
sun exposure and age, raise ceramide suﬃciently to trigger
apoptosis.
7. Possible Mechanismsof CeramideAction
The question remains: how does ceramide act as a signal
to induce apoptosis and other cellular responses? As this
lipid second messenger is further studied, it has become
apparent that it aﬀects multiple enzymes and proteins,
both directly and indirectly, to exert its eﬀects. As an
example, ceramide and ceramide-stimulating stresses are
known to activate the mitogen-activated protein kinase, p38
(e.g., [51–53]). Activation of p38 has also been observed
in keratinocytes upon treatment with pemphigus sera
[12], providing another possible link between pemphigus
and ceramide. Ceramide has also been shown to activate
both a protein phosphatase and a protein kinase, the so-
called ceramide-activated protein kinase identiﬁed as kinase
suppressor of ras (ksr) (reviewed in [13]). In addition,
ceramide, or its phosphorylated metabolite ceramide 1-
phosphate, appears to modulate the activity of enzymes
involved in alternative splicing to yield diﬀerential splicing
o fc e r t a i ng e n ep r o d u c t ss u c ha sc a s p a s e - 9( ap r o a p o p t o t i c
enzyme) and Bcl-xL (an antiapoptotic mediator) [54]. The
result is greater levels of the proapoptotic splice forms of
these proteins (Bcl-xS and caspase-9L) [54]. Ceramide also
aﬀects multiple proteins involved in the apoptotic pathway,
including Akt (an antiapoptotic, prosurvival protein that is
inhibited by ceramide action) and cathepsin D, a lysosomal
protease involved in apoptosis, among others (reviewed in
[55]). In addition, ceramide inhibits mitochondrial function
[14], thereby enhancing mitochondrial pathway-mediated
apoptosis (reviewed in [14]). Thus, ceramide functions
through multiple mechanisms as a proapoptotic cell signal
in many cell types including keratinocytes. In addition,
ceramide and its metabolites also likely play a role in
inﬂammation (reviewed in [56]).
Although ceramide seems to function generally as an
antiproliferativeand/orantisurvival(proapoptotic)signaling
molecule, there is emerging evidence that the cellular local-
ization of the generated ceramide may aﬀect the ultimate cell
response (reviewed in [17, 57]). For instance, overexpression
of a bacterial SMase in mitochondria, but not the cytoplasm,
Golgi apparatus, endoplasmic reticulum, plasma membrane,
or nucleus, triggers apoptosis in MCF7 breast cancer cells
[58]. In addition to eﬀects of compartmentalization, diﬀer-
ent ceramide species, possessing diverse fatty acids from 16
to 24 carbons in length, appear to have diﬀerent signaling
roles. There are ﬁve ceramide synthase isoforms, CerS1-5,
which have distinct speciﬁcities for the formation of various
ceramide species with diﬀerent carbon lengths (reviewed in
[17]). Knock down of CerS6, which produces 16 carbon-
containing ceramide (C16-ceramide), induces endoplasmic
reticulum stress-induced apoptosis, and overexpression of
this enzyme protects against ER stress and promotes squa-
mouscellcarcinomatumorgrowthinvivo[59].OntheotherDermatology Research and Practice 5
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Figure 3: Hypothesized Involvement of Sphingolipid Metabolism
in the Keratinocyte Response to Pemphigus Autoantibodies. Our
hypothesisisthatpemphigusautoantibodiesbindingtoDsgsresults
in the activation of sphingomyelinase (SMase) to produce ceramide
and phosphorylcholine. In an attempt to survive, keratinocytes
activate sphingomyelin synthase (SM synthase). The result is
an increase in phosphorylcholine and diacylglycerol levels and
a reduction in phosphatidylcholine. Stimuli that overwhelm the
ability of the cell to metabolize ceramide, such as cytokines or
ultraviolet (UV) light (or senescence), which increase ceramide
levels, are proposed to allow manifestation of pathologic skin
lesions. Note that UV light increases ceramide in at least two
ways: ﬁrst, by activation of both SMase-mediated [35]a n dde novo
ceramide production [19] and second, by decreasing ceramidase
activity/expression [60]. Ceramidases are key in the response of
keratinocytes to UV light because (1) they metabolize ceramide
and decrease its levels and (2) they generate sphingosine, which
can be converted to S1P (which allows cell survival) by the action
of sphingosine kinase. Indeed, knocking down sphingosine kinase
sensitizes keratinocytes to UV-induced apoptosis [60]. In addition,
ceramide and its metabolites can activate cytosolic phospholipase
A2 and cyclooxygenase-2, suggesting that eicosanoids might be
elevated and potentially contribute to the pemphigus disease
process (reviewed in [56]).
hand, overexpression of CerS1 (forming C-18 ceramide)
inhibits tumor formation, indicating that not only the site
of ceramide production but also the species generated is
important.
8.Hypothesis
We propose the idea that pemphigus autoantibodies, upon
binding to Dsgs, trigger sphingomyelin hydrolysis accom-
panied by a corresponding stimulation of sphingomyelin
synthase activity (Figure 3), as the cell attempts to reduce
proapoptotic ceramide amounts. If the cell is eﬃcient
enough, no change in ceramide or sphingomyelin levels may
occur, although a reduction in phosphatidylcholine levels
and an increase in phosphorylcholine release and diacyl-
glycerolquantitieswouldbeexpected.Inthiscase,acantholy-
sis and other hallmarks of pemphigus would not be observed
despite the ability of the antisera to bind Dsgs. Indeed, this
need for interaction between the binding of autoantibodies
and additional changes in ceramide metabolism may be
one explanation for the low levels of anti-Dsg antibodies
without concomitant disease seen in some individuals in the
El Bagre area [37] and fogo selvagem [61], as well as non-
pathogenic antibodies observed in some pemphigus patients
(reviewed in [62]). We also hypothesize that coincubation
of keratinocytes with pemphigus sera and cytokines, such as
FasL, or the combination of pemphigus sera and irradiation
with UV light, will result in enhanced levels of ceramide
relative to any of the agents alone. Since these combinations
would be expected to overwhelm the ability of the cell
to metabolize the pemphigus sera-induced production of
ceramide, we would also anticipate that cytokines and UV
light will act synergistically with pemphigus autoantibodies
to stimulate markers of apoptosis and cell death. Consistent
with this idea, inhibition of the action of some cytokines,
in particular FasL and TNF-α, can inhibit acantholysis in
experimental models of pemphigus (reviewed in [12]), and
a beneﬁcial action of new TNF-α blocking biological agents
in patients has also been reported [63, 64]. In addition,
ultraviolet irradiation is known to worsen pemphigus [11].
Similarly, there is a clear association between sunlight
exposure and El Bagre EPF [3]. The idea that UV induces
ceramide production that is at least partially compensated
for by an increase in ceramide clearance is supported
by the ﬁndings of Uchida and colleagues, who reported
(in abstract form) that both knock down of ceramidase
levels [60] and incubation with N-acyl-ethanolamine (NAE)
compounds that inhibit acidic and neutral ceramidases
sensitize keratinocytes to UV-induced apoptosis [65]. These
authors also showed that inhibition of the NAE-hydrolyzing
enzymes, NAE amidohydrolase, fatty acid amidohydrolase,
and NAE-hydrolyzing acid amidase, further exacerbates the
eﬀects of UV irradiation. NAE compounds occur naturally
and increase with cell stresses including UV exposure and
xenotoxics; thus, enhanced production of NAEs, as well as
decreased ceramidase activity/expression in response to UV,
could signiﬁcantly impair ceramide clearance [65]. It should
benotedthattheepidermishasbeenshowntoexpressallﬁve
known ceramidase isoforms, with some localized to the basal
layer and others to the diﬀerentiating compartments [66]. In
addition, alkaline (aCER1) and acid (AC) ceramidases are
upregulated during elevated extracellular calcium-induced
keratinocyte diﬀerentiation and appear to mediate the
diﬀerentiative eﬀects of calcium [67]. Thus, ceramidases
are clearly vital to epidermal physiology and perhaps also
pathophysiology, likely by both decreasing ceramide levels
and providing sphingosine for production of S1P [60].
On the other hand, it is possible that pemphigus sera
do not activate sphingomyelinase but rather stimulate the
activity of sphingomyelin synthase through the ligation of
cell adhesion molecules. It is widely recognized that cell
adhesion can elicit signal transduction processes (reviewed
in [68]). Perhaps antibody binding of Dsgs (or possibly
other cell surface proteins recognized by pemphigus autoan-
tibodies) results in stimulation of signaling and activation
of sphingomyelin synthase. This result would then predict
that antibody-mediated loss of the Dsg (or other cell6 Dermatology Research and Practice
surface proteins) would inhibit this signal, again leading to
apoptosis, either through elevations in ceramide levels or via
reductionsinproteinkinaseC-activatingdiacylglycerol.Dia-
cylglycerol appears to be a prosurvival, antiapoptotic signal
in most cell types (reviewed in [13]), presumably in part
through its ability to activate sphingosine kinase and stim-
ulate the production of S1P from ceramide [69]. Pemphigus
sera have also been reported to stimulate phosphoinositide
hydrolysis [70], which would result in the generation of
diacylglycerol. Alternatively, it is possible that antibody-
mediated loss of Dsg function (rather than of the protein
itself) may mediate the changes in cell signaling processes
that lead to blister formation in pemphigus. However, this
possibility is argued against by recent evidence suggesting
that Dsg-1 is proapoptotic, such that RNA interference
to decrease Dsg-1 protects keratinocytes against ultraviolet
irradiation-mediated apoptosis [71]. In any case, these ideas
should be testable by experiments to examine the eﬀect
of pemphigus sera on the levels of ceramide and other
sphingolipids in keratinocytes, and research into the role
of sphingolipid metabolism in the keratinocyte acantholytic
response to pemphigus autoantibodies seems warranted.
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